UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 4,149,346 Shares of Recursion Pharmaceuticals, Inc. $RXRX

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 183.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,408,524 shares of the company’s stock after buying an additional 4,149,346 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 1.58% of Recursion Pharmaceuticals worth $33,901,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in RXRX. ARK Investment Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 7.6% in the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company’s stock worth $184,174,000 after purchasing an additional 2,469,104 shares during the last quarter. Nuveen LLC bought a new stake in shares of Recursion Pharmaceuticals in the 1st quarter worth about $10,118,000. Kinnevik AB publ grew its holdings in shares of Recursion Pharmaceuticals by 12.8% in the 1st quarter. Kinnevik AB publ now owns 13,434,171 shares of the company’s stock worth $71,067,000 after purchasing an additional 1,528,503 shares during the last quarter. Jump Financial LLC grew its holdings in shares of Recursion Pharmaceuticals by 4,289.8% in the 1st quarter. Jump Financial LLC now owns 592,353 shares of the company’s stock worth $3,134,000 after purchasing an additional 578,859 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Recursion Pharmaceuticals by 627.6% in the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock worth $1,423,000 after purchasing an additional 232,038 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Insider Activity

In other news, insider Najat Khan sold 36,599 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the sale, the insider owned 668,197 shares of the company’s stock, valued at approximately $3,688,447.44. The trade was a 5.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $4.77 on Tuesday. The stock has a market capitalization of $2.07 billion, a P/E ratio of -2.68 and a beta of 0.91. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a 50 day moving average of $5.34 and a 200-day moving average of $5.27. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The firm had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. During the same period last year, the company posted ($0.40) earnings per share. The business’s revenue was up 33.3% compared to the same quarter last year. As a group, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $7.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.